Pharmaceuticals, Biotechnology and Life Sciences
Chad Harman, CEO of Psycheceutical, will share an overview of the Company and hold a brief Q&A for the Virtual…
TORONTO, Sept. 11, 2022 (GLOBE NEWSWIRE) — Axiom Real-Time Metrics (“Axiom”), the premier provider of unified eClinical solutions and services…
88% overall response rate (15 out of 17) from interim data of pan-FGFR treatment (FGFRi)-naïve FGFR2-fusion cholangiocarcinoma (CCA) patients treated at…
– Nirogacestat Treatment Resulted in Rapid, Sustained and Statistically Significant Improvements in Primary and All Key Secondary Efficacy Endpoints –…
Broad antitumor immune responses and demonstration of durable disease control from solid tumor patients who previously failed one or more…
-Sotigalimab in combination with neoadjuvant chemoradiation induced higher pathologic complete response rates, an important predictor of survival, in patients with…
PHILADELPHIA, Sept. 10, 2022 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery…
– Best-in-class profile demonstrated with repeat dosing across dose levels – – Antitumor activity observed in cold tumors with steady…
PORTLAND, Ore., Sept. 09, 2022 (GLOBE NEWSWIRE) — Chalice Brands Ltd. (CSE: CHAL) (OTCQB: CHALF) (the “Company” or “Chalice Brands”),…
— Fruquintinib treatment reduced the risk of death by 34% in metastatic colorectal cancer (0.66 HR) — — Increased disease control…